Applying inhibitors of the complement system that inhibit the C5a/C5aR1 axis may be a promising approach to shift the platelet-mediated response in ischemic diseases such as coronary or peripheral artery disease toward increased revascularization. The gene discussed is C5; the disease is peripheral arterial disease.